TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition November 3, 2023 long
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME August 30, 2023
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors June 6, 2023
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors May 25, 2023
